CTLA4 and neoplasm: To date, the most promising immune checkpoint inhibitors have been antibodies that block cytotoxic T lymphocyte antigen 4 (CTLA­4) and PD­1, which are expressed on T cells, or PD­ L1, which is expressed on certain immune cell subsets and is aberrantly expressed on tumor cells.